Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Guardant Health ( (GH) ) has provided an update.
On January 11, 2026, Guardant Health reported preliminary, unaudited results indicating that 2025 was a breakout year, with total revenue for the year ended December 31, 2025 rising 33% to approximately $981 million and fourth-quarter revenue up 39% to about $280 million versus 2024, driven by strong growth in both oncology and screening volumes. The company reported around 276,000 oncology tests for 2025, up 34%, and a rapid ramp in its Shield colorectal cancer screening franchise to approximately 87,000 tests for the year—including about 38,000 in the fourth quarter compared with 6,400 a year earlier—while expanding Shield to include multi-cancer detection findings; despite this top-line momentum, Guardant remained cash-flow negative, with preliminary free cash flow of roughly negative $54 million in the fourth quarter and negative $233 million for the full year, though it ended 2025 with approximately $1.3 billion in cash and marketable securities and plans to release audited 2025 results in February 2026.
The most recent analyst rating on (GH) stock is a Buy with a $120.00 price target. To see the full list of analyst forecasts on Guardant Health stock, see the GH Stock Forecast page.
Spark’s Take on GH Stock
According to Spark, TipRanks’ AI Analyst, GH is a Neutral.
Guardant Health’s strong technical momentum and positive earnings call insights are offset by financial instability and valuation concerns. Strategic partnerships and recent corporate events provide a supportive backdrop for future growth, but profitability and financial health remain critical areas for improvement.
To see Spark’s full report on GH stock, click here.
More about Guardant Health
Guardant Health, Inc., founded in 2012 and based in Palo Alto, is a precision oncology company that develops advanced blood and tissue tests, supported by real-world data and AI analytics, to improve cancer care across screening, recurrence monitoring and treatment selection. The company focuses on liquid biopsy technologies, including its Shield blood-based colorectal cancer screening test and a portfolio of oncology assays, targeting earlier detection and more personalized treatment of cancer for patients worldwide.
Average Trading Volume: 2,547,700
Technical Sentiment Signal: Buy
Current Market Cap: $14.07B
For an in-depth examination of GH stock, go to TipRanks’ Overview page.